Louisiana filed an emergency motion with the Supreme Court asking justices to maintain the 5th Circuit's ban on mailing mifepristone, a medication abortion drug. The state seeks to preserve an appeals court order that blocks the U.S. Postal Service from delivering the drug across state lines.

The 5th Circuit previously issued the mailing restriction, creating a direct conflict with FDA approval of mifepristone for mail delivery. Mifepristone, typically used with misoprostol, comprises the standard two-drug protocol for medication abortion nationwide.

Louisiana's motion attempts to prevent the Supreme Court from dissolving or modifying the 5th Circuit's order pending full briefing and judicial review. The state argues the restriction should remain enforceable while the case proceeds through the courts.

This dispute reflects the broader post-Dobbs landscape, where individual states aggressively pursue abortion restrictions despite federal approval of abortion medications. The 5th Circuit, known for conservative rulings, has repeatedly blocked FDA expansion of medication abortion access.

The Supreme Court must decide whether to intervene. Justices could let the 5th Circuit order stand, lift it entirely, or impose a temporary stay allowing limited mail access while litigation continues. The decision carries immediate practical consequences: women in states without direct abortion access rely on mail delivery to obtain medication abortion pills.

Federal law and FDA regulations authorize mifepristone's mailing under specific conditions. Louisiana's position challenges federal regulatory authority directly, arguing states can override federal health policy within their borders.

The case touches core constitutional tensions between state abortion regulation, federal drug approval authority, and individual access to lawful medication. A Supreme Court decision upholding the mailing ban would substantially restrict medication abortion availability across America, even in states where abortion remains legal.

THE TAKEAWAY: Louisiana seeks to cement the 5th Circuit's mifepristone mailing ban